Comment on: Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients

被引：2
|
作者：
Barone, Federico [1 ,2 ]
Giacomelli, Andrea [1 ,2 ]
Casalini, Giacomo [2 ]
Corbellino, Mario
Lai, Alessia [1 ]
Gori, Andrea [1 ,3 ,4 ]
Antinori, Spinello [1 ,2 ]
机构：
[1] Univ Milan, Dipartimento Sci Biomed & Clin, Milan, Italy
[2] Luigi Sacco Hosp, Infect Dis Unit 3, ASST Fatebenefratelli Sacco, Milan, Italy
[3] Luigi Sacco Hosp, Infect Dis Unit 2, ASST Fatebenefratelli Sacco, Milan, Italy
[4] Univ Milan, Ctr Multidisciplinary Res Hlth Sci MACH, Milan, Italy
来源：
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2024年 / 79卷 / 09期
关键词：
D O I：
10.1093/jac/dkae234
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：2400 / 2402
页数：3
相关论文
共 50 条
  • [31] THE USE OF SINGLE THERAPY WITH TOCILIZUMAB VERSUS COMBINATION THERAPY WITH REMDESIVIR IN SARS-COV-2 PATIENTS IN EL PASO TEXAS
    Almaghlouth, Nouf K.
    Shah, Sidra
    Haq, Syed
    Anyiam, Felix E.
    Attia, Mohamed J.
    Guevara, Roberto
    Antony, Suresh
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2021, 36 (SUPPL 1) : S27 - S27
  • [32] Characteristics of virus and antibody response in an immunocompromised patient with persistent SARS-CoV-2 infection
    Yazawa, Shunsuke
    Fukuyama, Kei
    Kawakami, Rie
    Itamochi, Masae
    Higashi, Daiki
    Tsuji, Noriaki
    Nakamura, Masahiko
    Oishi, Kazunori
    Kaya, Hiroyasu
    Tani, Hideki
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2025, 31 (02)
  • [33] Response to mRNA SARS-CoV-2 vaccination evaluated by B-cell receptor repertoire after tixagevimab/cilgavimab administration
    Funakoshi, Yohei
    Yakushijin, Kimikazu
    Ohji, Goh
    Matsutani, Takaji
    Hojo, Wataru
    Sakai, Hironori
    Matsumoto, Sakuya
    Watanabe, Marika
    Kitao, Akihito
    Saito, Yasuyuki
    Kawamoto, Shinichiro
    Yamamoto, Katsuya
    Koyama, Taiji
    Nagatani, Yoshiaki
    Kimbara, Shiro
    Imamura, Yoshinori
    Kiyota, Naomi
    Ito, Mitsuhiro
    Minami, Hironobu
    BRITISH JOURNAL OF HAEMATOLOGY, 2023,
  • [34] Antiviral combination treatment strategies for SARS-CoV-2 infection in immunocompromised patients
    Sepulcri, Chiara
    Bartalucci, Claudia
    Mikulska, Malgorzata
    CURRENT OPINION IN INFECTIOUS DISEASES, 2024, 37 (06) : 506 - 517
  • [35] Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants
    Tuffy, Kevin M.
    Ahani, Bahar
    Aksyuk, Anastasia A.
    Avila, Miles
    Brady, Tyler
    Kijak, Gustavo H.
    Koh, Gavin
    Levin, Myron J.
    Roe, Tiffany L.
    Schuko, Nicolette
    Thissen, Jesse
    Ustianowski, Andrew
    Zhang, Tianhui
    Kelly, Elizabeth J.
    Streicher, Katie
    JOURNAL OF INFECTIOUS DISEASES, 2023, 228 (08): : 1055 - 1059
  • [36] Tixagevimab plus cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence
    Convertino, Irma
    Ferraro, Sara
    Cappello, Emiliano
    Valdiserra, Giulia
    Bonaso, Marco
    Tuccori, Marco
    EXPERT OPINION ON DRUG DISCOVERY, 2023, 18 (03) : 231 - 245
  • [37] Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters
    Conte, William L.
    Golzarri-Arroyo, Lilian
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 63
  • [38] Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of monoclonal antibody resistant variants
    Kamboj, Mini
    Laracy, Justin C.
    Usiak, Shauna
    Babady, N. Esther
    Yan, Judy
    Seo, Susan K.
    JOURNAL OF INFECTION, 2023, 87 (03) : 282 - 285
  • [39] Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants
    Roe, Tiffany L.
    Brady, Tyler
    Schuko, Nicolette
    Nguyen, Amy
    Beloor, Jagadish
    Guest, Johnathan D.
    Aksyuk, Anastasia A.
    Tuffy, Kevin M.
    Zhang, Tianhui
    Streicher, Katie
    Kelly, Elizabeth J.
    Kijak, Gustavo H.
    MICROBIOLOGY SPECTRUM, 2023, 11 (02)
  • [40] Tixagevimab and cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters
    Conte, W.
    Golzarri-Arroyo, L.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 868 - 869
12345